Periodic PSA-based screening remains the most commonly used screening method for early detection of prostate cancer, closely followed by diagnostic TRUS, MRI, and PSMA-positron emission tomography (PSMA-PET). This evidence concerns the gene FOLH1 and prostate cancer.